Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Alnylam Pharmaceuticals' stock to be halted Wednesday as FDA advisory panel reviews treatment for the Cardiomyopathy of ATTR Amyloidosis
07:12am, Wednesday, 13'th Sep 2023
Alnylam Pharmaceuticals Inc. ALNY, +3.89% said Wednesday its stock will be halted on Nasdaq through the day as a regulatory advisory committee will meet to review its new drug application for a treatm
Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility
08:26am, Saturday, 09'th Sep 2023
Alnylam has an upcoming FDA advisory committee meeting on the company's application for Onpattro in ATTR-CM, and I see some risk of a negative committee vote. Onpattro has met or exceeded the efficacy
Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study
08:17am, Friday, 08'th Sep 2023
Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.
3 Stocks to Buy For the COVID Resurgence
08:44am, Thursday, 07'th Sep 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting
Alnylam hypertension drug meets main goal in mid-stage study
07:15am, Thursday, 07'th Sep 2023
Alnylam Pharmaceuticals said on Thursday its experimental therapy for hypertension met the main goal in a mid-stage study.
Alnylam to appeal ruling on patents related to Moderna's COVID vaccines
06:05pm, Friday, 25'th Aug 2023
Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID-19 vaccine Spi
Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss
12:47pm, Friday, 04'th Aug 2023
Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2023 Earnings Call Transcript
01:40pm, Thursday, 03'rd Aug 2023
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President-Investor Relations and Corpora
Alnylam (ALNY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
12:46pm, Thursday, 03'rd Aug 2023
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
08:30am, Wednesday, 02'nd Aug 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord
Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development Timeline
09:05am, Sunday, 30'th Jul 2023
Alnylam partnered Roche to develop and commercialize zilebesiran for the treatment of hypertension. Alnylam's share price has not benefited as the announcement was followed by the company revealing a
Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche
02:35pm, Monday, 24'th Jul 2023
Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.
Roche enters partnership with Alnylam for hypertension therapy
01:18am, Monday, 24'th Jul 2023
Swiss pharmaceutical group Roche said on Monday it had entered into a partnership with U.S. biopharmaceutical company Alnylam to co-develop and co-commercialise zilebesiran, a therapy to treat hyperte
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know
11:26am, Thursday, 20'th Jul 2023
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
09:54am, Thursday, 20'th Jul 2023
Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.
